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Chronic persistent airway obstruction has been observed in moderate-to-severe asthmatics
despite treatment with inhaled corticosteroids. We investigated which airway changes were
associated with this obstruction.
High-resolution computed tomography (HRCT) was performed at study entry and reexa-
mined at the time of follow-up when the FEV1 reached a maximally constant level after treat-
ment for 1 year or more with inhaled corticosteroids. Bronchial wall area and air trapping
extent were compared in the recovered group (n Z 18) and the persistent airway obstruction
group (n Z 14).
Bronchial wall area and air trapping of the initial HRCTwere similar between the two groups.
On follow-up HRCT, air trapping was markedly decreased in the recovered group comparedcomputed tomography; Post-BD FEV1, post-bronchodilator forced expiratory volume in 1 s; dAT,
and 2nd HRCT exam; d post-BD FEV1, difference post-BD FEV1 value between at initial and 2nd HRCT
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Air trapping on airway obstruction in asthma 787with that on initial HRCT (P Z 0.017), whereas bronchial wall area did not change. In the
persistent-airway-obstruction group, these two parameters did not change during follow-up.
When follow-up HRCT was compared, air trapping was significantly greater in the persistent-
airway-obstruction group than in the recovered group (P Z 0.003). Difference post-
bronchodilator FEV1 value between at initial and 2nd HRCT exam was correlated with differ-
ence air trapping value between at initial and 2nd HRCT exam(%) on the follow-up HRCT
(PZ 0.017). The presence of persistent airflow obstruction were significantly associated with
the air trapping % difference between initial and 2nd time (RR Z 1.70, P Z 0.018).
Persistence of AT could be a main contributing factor to chronic persistent airflow obstruc-
tion in asthma.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic inflammatory airway disease, charac-
terized by airflow limitation and airway hyper-responsive-
ness.1 However, asthma patients consist of several
subgroups defined by etiology, pathology, severity, and
response to treatment.2 High doses of inhaled corticoste-
roids can relieve airflow obstruction in asthmatics.
However, a proportion of patients fail to recover normal
lung function. Such persistent airflow obstruction is one
of the specific asthma phenotypes and comprises fewer
than 5% of all asthmatics.3
This subgroup has several characteristics that differ
from typical asthma. Eosinophilic airway inflammation is
the characteristic abnormality in both atopic and nonatopic
asthma.4 However, recent studies suggest that neutrophils
are predominant in the airways of severely affected
patients.5,6 Additionally, thickening of the reticular base-
ment membrane and increased airway smooth muscle are
associated with persistent airflow obstruction in severe
asthma.6,7 Thus, the examining differences in airway
inflammation and airway wall changes may help in pre-
dicting the effectiveness of asthma therapies including
inhaled corticosteroids in asthma subgroups.
In evaluating airway structural changes in asthma,
histological examinations using bronchoscopic biopsies are
very useful, but availability is limited in severe asthmatics.
For the past two decades, HRCT has been used as a nonin-
vasive method to assess bronchial wall thickness and air
trapping to reflect the changes in large and small airways.8
Severe asthma is characterized by thickened bronchial
walls and increased air trapping on HRCT.9,10 These large
and small airway changes are considered to be responsible
for treatment-refractory, chronic, persistent airway
obstructions. However, few studies have evaluated longi-
tudinal morphological changes in these parameters. The
purpose of this study was to evaluate large and small
airway changes on HRCT for the structural characterization
of the unresponsiveness to inhaled corticosteroids, leading
to persistent airflow obstruction in patients with asthma.
Materials and methods
Subjects
We enrolled patients with moderate or severe asthma
according to the Global Initiative for Asthma (GINA)guidelines11 at a university hospital. Moderate-to-severe
asthma was defined as post-bronchodilator forced expira-
tory volume in 1 s (post-BD FEV1) of <75% of the predicted
value, two or more episodes of nocturnal symptoms per
week, and limitation of activities with asthma symptoms
present.11 Subjects had not taken any inhaled or systemic
corticosteroid over the previous 4 weeks before the first
HRCT examination. All subjects underwent a standardized
assessment, which included complete blood count, total
IgE, chest posteroanterior radiography, allergy skin-prick
tests, and spirometry.12 Exclusion criteria included respi-
ratory infections within 4 weeks of screening, smoking
history of >10 packs per year, chronic obstructive pulmo-
nary disease or post-BD FEV1 of >75% predicted value at
screening.
This study was approved by the hospital ethics
committee. Written consent was obtained from all patients.
Study design
At screening, the subjects underwent lung function tests
and HRCT. Subjects with bronchiectasis, emphysema, or
other parenchymal lung diseases on HRCT were excluded.
Immediately after examination, systemic and/or inhaled
corticosteroid treatment was started, according to GINA
guidelines.11 During the study period, all subjects main-
tained higher doses of inhaled corticosteroids (>1000 mg
fluticasone per day) combined with long-acting b-agonists
and additional therapies to achieve optimal symptom relief
and maximum FEV1 for 12 months or more. When the post-
BD FEV1 level reached a maximum, HRCT was reevaluated.
Maximal post-BD FEV1 level was defined as <10% variation
observed on two or more consecutive FEV1 measurements
with a 2-month interval after continuous medications for 12
months or more. Subjects were divided into two groups by
post-BD FEV1 % levels: the recovered group with >75%, and
the persistent airway obstruction group with <75%.
Thin-slice CT scanning and radiological evaluation
All subjects underwent volumetric thin-section CT scanning
of the chest using a 16-slice helical CT (Somatom Sensation
16, software version VA20; Siemens Medical Solutions,
Forchheim, Germany). The measurement of HRCT findings
has been described previously.13 Inspiration and expiration
scans were obtained at the end of full inspiration and at the
end of full expiration.14 We used the following parameters:
788 S.-W. Park et al.120 kVp, 180 mAs, 1-mm table feed/rotation, 1-mm colli-
mation, and a 0.5-mm interval. Image data were recon-
structed with 1.0-mm thicknesses and 10-mm intervals
using a bone algorithm.
Images were viewed at two window levels: 450 HU for
bronchial wall area(%) and 700 HU for air trapping(%). All
images were displayed at the lung window setting using
a picture-archiving and communication system (PACS) work
station (Starpacs, Infinitt Technology). These findings were
defined according to the glossary of terms recommended by
the Fleischner Society.15 Airway images were viewed on
a work station using a magnification of 5, and measure-
ments of outer (D) and internal (L) diameters of the bronchi
were made using electronic calipers by two experienced
thoracic radiologists. All bronchi with a D diameter of
>1.5 mm and a ratio of the long-to-short D diameter < 1.5
were measured on each slice of the end-inspiration scans.
Because oblique sections can influence wall thickness,
bronchi showing a ratio of the long-to-short D diame-
ter < 1.5 were analyzed.
Wall area(WA) was calculated as a percentage of total
airway cross-sectional area according to the following
formula13:
WAð%ÞZ
 
pðD=2Þ2pðL=2Þ2
pðD=2Þ2
!
þ 100
To measure air trapping, the lung was divided into six
zones (right and left upper, middle, and lower) by one- and
two-thirds of the vertical distance between the lung apices
and the domes of the diaphragm. Air trapping was defined
by the decreased attenuation of pulmonary parenchyma,
manifested as a less-than-normal increase in attenuation
during expiration, according to the definition of the
Fleischner Society.15
Thus, lung attenuation and air trapping area measure-
ments were performed on similar anatomical levels at
inspiration and expiration. The reader selected HRCT
sections according to anatomical landmarks and used the
software to measure the difference between inspiratory
and expiratory median lung attenuation, calculated for the
whole lung, as described previously. Focal areas of relative
lucency in the superior segments of the lower lobes were
excluded from analysis because they can be seen in normal
subjects on expiratory scans.16 The low attenuation areas
of emphysema and bullae were also excluded.
Air trapping was calculated as the percentage of the
involved area to the cross-sectional area from each zone.
Intra- and inter-observer variation were assessed by plot-
ting the difference between the two wall area and air
trapping measurements against the mean value of each.17
To assess intra- and inter-observer variability of parame-
ters, the kappa coefficient of agreement (k) was
computed.18
Statistical analysis
Data are expressed as means  SEM or medians and
inter-quartile ranges. The SPSS/PC þ program (SPSS, Inc.,
Chicago, IL) was used for the statistical analyses. Man-
neWhitney U test or the chi-squared test was used
to compare differences between the recovered groupand persistent airway obstruction group. Initial and
follow-up differences in variables in the intra-group were
determined by using the Wilcoxon signed rank test.
Correlations between the data were assessed using
Spearman’s rank test. Finally, multivariate log-binomial
regression models were used because of the presence of
common outcome variables to estimate relative risks (RRs)
and 95% confidence intervals (CIs) for the presence of
persistent airflow obstruction by including the initial wall
area (Model 1), the initial air trapping (Model 2), the
difference between the initial and follow-up wall area
(Model 3) and the difference between initial and follow-up
air trapping (Model 4). Models 1 and 2 were adjusted
for age, gender, smoking history, atopy, and symptom
duration. Model 3 was further adjusted for initial wall
area and Model 4 was further adjusted for initial air
trapping. P values < 0.05 were considered to indicate
statistical significance.Results
Demographic and physiological characteristics
of the study subjects
In total, 32 patients with moderate-to-severe asthma were
enrolled; 14 patients developed persistent airway obstruc-
tion during treatment (Persistent airway obstruction group;
Table 1). There was no significant difference in age,
gender, frequency of atopy, smoking, or duration of asthma
between the two groups. The mean length of follow-up
duration was similar between the two groups (2.1 vs. 2.7
years). On the initial day of the study, all study subjects had
post-BD FEV1s of <75% predicted. There was no significant
difference in lung function, including FVC, FEV1, and FEV1/
FVC values, between the two groups (Table 2). At the
second HRCT examination, the post-BD FEV1 had not
changed in the persistent airway obstruction group from
that at the initial examination (55.2  4.4% vs. 59.2  3.0%
of the predicted value; P Z 0.37), whereas the recovered
group showed a marked improvement in FEV1 (51.1  5.4%
vs. 86.6  3.1% of the predicted value; PZ 0.001). Changes
in FVC and FEV1/FVC were comparable to changes in FEV1 in
both groups (Table 2). Thus, the follow-up FEV1/FVC was
significantly higher in the recovered group compared with
the persistent airway obstruction group (73.4  2.9% vs.
58.7  4.1%; P Z 0.002).
Comparison of parameters on HRCT findings
between recovered group and persistent airway
obstruction group
In total, 1092 bronchi were measured using thin-section
CT scanning (630 in 18 patients in the recovered group,
462 in 14 patients in the persistent airway obstruction
group; range, 16e21 bronchi on HRCT scanning per
subject). The mean diameters of the outer airways of the
measured bronchi were similar in the recovered group and
persistent airway obstruction group (5.6  0.24 vs.
5.7  0.27 mm, respectively; P > 0.05). The k values for
inter- and intra-observer agreement of wall area were 68%
Table 1 Demographic characteristics of study subjects.
Recovered group Persistent airflow
obstruction group
p-value, comparison
between groups
n Z 18 n Z 14
Age (y)a 58.4  3.2 62.3  4.2 NS
Male (%) 11(61.1%) 8 (57.1%) NS
Follow-up duration (y)a 2.1  0.4 (1.6e3.6) 2.7  0.9 (1.6e4.3) NS
Asthma duration (y)a 11.0  2.7 13.7  5.3 NS
Smoking
SM (N) 2 1
ES (N) 8 5 NS
NS (N) 8 (44.4%) 8 (57.1%)
Pack-yrsb 5 (0e10) 0 (0e10) NS
Atopy (%) 6 (33.3%) 7 (50.0%)
Total IgE (IU) 358.8  78.7 352.8  96.1 NS
Dose of Inhaled Steroid (mg/day),a,c 1375  87 1367  96 NS
Oral steroid (%) 61% 64% NS
Leukotrien receptor antagonist (%) 35% 41% NS
Exacerbation, numberb 1 (0e4) 2 (0e7) NS
Data are presented as N, percentage.
a Mean  SEM.
b Median (range).
c Fluticason equivalent SM: current smoker, ES: ex-smoker, NS: never smoker.
Air trapping on airway obstruction in asthma 789and 77%, respectively. Wall area at the initial HRCT was
similar between the recovered group and persistent
airway obstruction group (66.6  1.5 vs. 65.6  1.6%;
P Z 0.625). Wall area values on the second HRCT were
also similar between the recovered group and persistent
airway obstruction group (65.1  1.2 vs. 67.2  1.8%;
PZ 0.568; Table 3). Air trapping values in the initial HRCT
were comparable between the recovered group and
persistent airway obstruction group (53.4  4.2 vs.
50.7  2.6%, P Z 0.160). However, air trapping was
significantly decreased in the recovered group during the
second HRCT compared with that of the initial HRCT
(53.4  4.2 vs. 41.6  3.3%; P Z 0.001). In contrast, air
trapping did not change in the persistent airway obstruc-
tion group despite treatment between the initial andTable 2 Pulmonary function tests at initial and 2nd exam of HR
Recovered group Persist
n Z 18 n Z 1
PFT % of predicted
BDFVC
Initial 68.6  4.9 72.2 
2nd exam of HRCT 86.2  2.5 77.0 
Intra-group comparison <0.001 0.414
BDFEV1
Initial 51.1  5.4 55.2 
2nd exam of HRCT 86.6  3.1 59.2 
Intra-group comparison < 0.001 0.379
BDFEV1/FVC
Initial 57.0  2.7 54.3 
2nd exam of HRCT 73.4  2.9 58.7 
Intra-group comparison < 0.001 0.232second measurements (50.7  2.6 vs. 54.2  2.2%;
P Z 0.109). The inter-observer agreement level was 73%
for air trapping. The k values for air trapping ranged from
0.48 to 0.60, indicating fair-to-good agreement.19 The
intra-observer agreement rate was 86% for air trapping; all
k values were >0.75.Correlations of parameters on HRCT findings with
lung function test in the patients
Bronchial wall area and air trapping were not correlated
with post-BD FEV1% predicted values that were measured
at initial examination (RZ 0.336, PZ 0.06; RZ 0.337,
P Z 0.06; respectively, Fig. 1). However, air trapping wasCT.
ent airflow obstruction group Inter-group comparison
4 (p-value)
4.9 0.703
4.0 0.057
4.4 0.493
3.0 < 0.001
4.3 0.278
4.1 0.002
Table 3 HRCT findings at initial and 2nd exam.
Recoveredgroup Persistent airflow
obstruction group
Inter-group comparison
(p-value)
n Z 18 n Z 14
Bronchialwall area (%)
Initial 66.6  1.5 65.6  1.6 0.513
2nd exam 65.1  1.2 67.2  1.8 0.568
Intra-groupcomparison(p-value) 0.304 0.3
Air trapping (%)
Initial 53.4  4.2 50.7  2.6 0.16
2nd exam 41.6  3.3 54.2  2.2 0.001
Intra-groupcomparison(p-value) 0.007 0.109
790 S.-W. Park et al.inversely correlated with post-BD FEV1% predicted that
were measured at 2nd HRCT examination (R Z 0.397,
P Z 0.03, Fig. 1). Differences in air trapping between the
initial and second examination correlated well with post-BD
FEV1 % of predicted between the initial and second exam-
inations (R Z 0.440, P Z 0.017; Fig. 2).Figure 1 Correlation between parameters on HRCT findings an
trapping(%)_I, bronchial wall area_I, and post-bronchodilator FEV1
visit. Air trapping(%)_F, bronchial wall area_F, and post-bronchodila
at 2nd HRCT exam. Air trapping at 2nd HRCT exam (air trapping(%)
P Z 0.03). Open and closed circles represent persistent airway obPrediction models for the presence of persistent
airflow obstruction in response to maximal steroid
treatment in the HRCT findings
After adjusting for age, gender, atopy, smoking, asthma
duration, and initial air trapping (%), the log-binomiald Post-BD FEV1(%) at the initial and 2nd exam of HRCT. Air
(%)_I means the values of these parameters measured at initial
tor FEV1(%)_F means the values of these parameters measured
_F) is inversely correlated with Post-BD FEV1(%) (R Z 0.397,
struction group and recovered group, respectively.
Figure 2 Correlation between difference of air trapping(%)
and post-bronchodilator FEV1(dPost-BD FEV1)(%) at the 2nd
exam of HRCT. Difference of air trapping(%) is inversely
correlated with d Post-BD FEV1(%) (R Z 0.44, P Z 0.017).
Open and closed circles represent persistent airway obstruc-
tion group and recovered group, respectively. Difference of air
trapping (%) and differences of Post-BD FEV1% is calculated by
the values that from initial minus at 2nd HRCT exam
respectively.
Air trapping on airway obstruction in asthma 791regression model revealed that differences between the
initial and the second examination in air trapping was an
independent risk factor for the presence of persistent
airflow obstruction (RR, 1.70; 95% CI, 1.09e2.64; Table 4).
Discussion
In the present study, we found that changes in small
airways, but not large airways, may have an impact on the
unresponsiveness to treatment with higher doses of inhaled
corticosteroids. Air trapping was significantly decreased in
the recovered group, but was not changed in the persistent
airway obstruction group at the second HRCT compared
with the initial HRCT. This suggests that persistent airflow
limitation, despite intensive asthma treatment, is primarily
due to the persistence of small airway changes. Small
airway changes have been observed in several subtypes of
asthma. The duration of this study was over 1 year for two
reasons. First, treatment duration of 1 year properly
reflects seasonal variation in environmental factors (aller-
gens, air pollutants, infection) that could affect asthma
control. Second, extensive evaluation and proper treat-
ment of asthma over a 6-month period by specialists isTable 4 Multivariate log-binomial regression models for the pr
months of treatment with maximal dose of inhaled steroid.
Variables
Model 1 Initial bronchial wall area (%)
Model 2 Initial air trapping (%)
Model 3 Difference bronchial wall area (%)a
Model 4 Difference air trapping (%)a
Model 1 and 2 were adjusted for age, sex, smoking (ever/never), atopy
initial bronchial wall area Model 4 included variables in Model 2 and
a Difference was calculated by initial minus 2nd HRCT exam.required to define chronic severe refractory asthma.20 To
our knowledge, air trapping on HRCT scans has not previ-
ously been longitudinally analyzed with anti-asthma treat-
ments for a more than 1 year in moderate-to-severe
asthmatics, although a 3-month follow-up study has been
reported.21 Tunon-de-Lala et al. reported that air trapping
measured using HRCT was partially diminished after 3
months of treatment with inhaled corticosteroids in
patients with uncontrolled mild-to-moderate asthma.21 The
discrepancy between the results in this study and ours may
be due to a milder degree of airway obstruction (89.2% of
FEV1 predicted) and a younger age group (35.3  10.7
years) in the Lara study.
Air trapping on HRCT may be produced by a combination
of multiple factors, including intrabronchiolar mucoid
impaction, peribronchiolar inflammation, and bronchiolar
wall remodeling, which includes muscular hypertrophy on
pathology. Inflammatory debris consists of plasma exudates
and inflammatory cells, particularly eosinophils and
epithelial cells, that are sloughed from the airway
surface.22 In addition to airway inflammation, remodeling
with collagen deposition and smooth muscle hypertrophy
were also found throughout the peripheral airways.23 The
pattern of inflammation and structural changes in small
airways may vary according to the severity and duration of
asthma.24 Paganin and colleagues reported on the evolution
of CT abnormalities after antiasthmatic therapy.25 Within
1e2 weeks, mucoid impaction, acinar patterns, and lobar
collapse could be reversed, whereas bronchial wall thick-
ness, bronchiectasis, and emphysema were unchanged.25
The reversibility of remodeled airways is supported, in
part, by a pathological study showing that subepithelial
collagen deposition, one component of bronchial wall
thickening, was reduced significantly in asthmatic patients
who had received intensive anti-inflammatory therapy for 6
months.26
Our results reveal that bronchial wall thickening was not
reversed in asthmatic patients, even in the recovered
group, members of which showed improvements in FEV1.
This may be because the subjects had no reversible bron-
chial wall component at the initial HRCT examination
because many of them had been on inhaled corticosteroids
therapy during the 4 weeks prior to the initial HRCT
examination. It may also possible that such a difference in
Wall thickening could not be detected between the two
groups because of the small sample size. However, air
trapping was improved in more than half of the study
subjects, suggesting that anatomical changes in smallesence of persistent airflow obstruction response to over 12
RR 95% CI p-value
1.01 (0.91e1.13) 0.79
1.01 (0.97e1.05) 0.62
1.04 (0.92e1.19) 0.515
1.7 (1.09e2.64) 0.018
and symptom duration Model 3 included variables in Model 1 and
initial air trapping.
792 S.-W. Park et al.airways still had reversible components in these moderate-
to-severe asthmatics in the present study.
A few studies have found risk or predictive factors for
the development of fixed airway obstruction in asth-
matics.27 Lee et al. reported that sputum eosinophilia,
smoking, longer asthma duration, and older age were
associated with persistent airflow obstruction in patients
with asthma.27 The lack of impact of inhaled corticosteroid
treatment on air trapping in the chronic persistent airway
obstruction group may not be due to the duration of
treatment in the present study, because the two groups
had similar durations. Smoking has been considered to be
one of the main risk factors for the development of fixed
airflow obstruction or persistent airflow limitation that is
refractory to treatment.27 In the present study, smoking
may not have been related to steroid treatment under-
responsiveness because smoker and ex-smoker preva-
lences were comparable between the two study groups,
and smokers who smoked less than 10 packs per year were
included in the study. Although we exclude the possibility
of COPD from our study asthmatics by smoking history and
emphysema by HRCT, it still possible that some of patients
might have overlap syndrome caused by other than ciga-
rette smoking because some phenotype of COPD have only
air trapping without emphysema by HRCT analysis.28
Ten Brinke et al. reported that adult onset of disease,
sputum eosinophilia, and airway hyper-responsiveness were
associated with persistent airflow limitation.29 Other
reports have shown that patients with severe asthma with
irreversible airflow obstruction had high levels of peripheral
eosinophilia, and high degrees of bronchial wall thickening
on HRCT scans.30 Additionally, different types of airway
inflammation may be related to different responses to
steroid treatment. Eosinophilic asthma responds well to
inhaled corticosteroids. In contrast, neutrophilic asthma
appears to be relatively corticosteroid-resistant. Recently,
Choi et al. reported that patients with persistent airflow
obstruction due to refractory asthma have neutrophil-
dominant airway inflammation.31 Busacker et al. reported
that a high level of airway neutrophils was a risk factor
associated with air trapping in patients with severe
asthma.32 Thus, the relationship between neutrophilic
inflammation and small airway changes in moderate-to-
severe asthma unresponsive to steroid treatment should
be evaluated in the future. In our study, the frequency of
persistent airflow obstruction was 44% (14 from 32
subjects), which is higher than 5% of all asthmatics.3 This
may be derived from the different population of study
subjects. The present study was investigated in moderate-
to-severe asthmatics on long term e high dose asthma
medication while the latter was observed in all subjects of
mild to very severe asthma. A limitation of this study was
the small number of patients. However, strengths of the
study include that it was prospectively and longitudinally
performed over 12 months to measure HRCT and lung
function test over the same time interval.
In summary, in this study, we showed that the devel-
opment of persistent airflow obstruction was associated
with small airway changes, as reflected in persistent air
trapping in adult moderate-to-severe asthma even after
prolonged treatment with high doses of inhaled cortico-
steroid. This impairment should be a therapeutic target infuture studies so that specific rationales can be developed
for treatment or prevention of persistent airflow obstruc-
tion in moderate-to-severe persistent asthma.
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